Van Gogh Research

$ALLR tbh I cant imagine ever giving Relacorilant to my worst enemy.. imagine having a few months left to one's life w PROC and dealing w non stop puking diarrhea no appetite fatigue nausea rashes not to mention real life-threatening serious side effects..

$ALLR WNT in plain english: it's a signaling network that when overactivated tells cancer cells to keep dividing, resist treatment, and behave like stem cells. that stem cell phenotype is a core reason advanced CRC is so hard to kill with chemo. (So normal cells have a defined identity and a defined job. A colon cell is a colon cell. It does its thing and eventually dies on schedule. Cancer cells start losing that defined identity, and when WNT is overactivated, they start reverting toward a more primitive, stem-like state. Stem cells by definition are cells that haven't fully committed to being any particular thing yet. They're flexible, they self-renew, and they're hard to kill because they're built to survive and keep dividing. That's great when you're building an embryo. It's terrible when it's happening inside a tumor. What it means practically in CRC: When WNT is firing constantly in a colorectal cancer cell, that cell starts behaving like it's a stem cell again. It becomes better at resisting chemotherapy, better at surviving in hostile environments, better at seeding new tumors in distant organs (metastasis), and better at repopulating the tumor after treatment knocks it back. This is actually a major reason why CRC responds to chemo initially and then comes roaring back. You kill most of the tumor but the cells with this stem-like phenotype survive, and they rebuild it.) 6/

$ALLR since people are asking, let me put that hazard ratio in context by comparing it to the drug that just got FDA approved in the same disease Corcept's relacorilant (Lifyorli), approved March 25, 2026 for platinum resistant ovarian cancer. ROSELLA Phase 3 data: -hazard ratio: 0.65 (35% risk reduction) -median OS: 16.0 months vs 11.9 months control -requires IV nab-paclitaxel (not oral monotherapy) -grade 3+ adverse events in 74.5% of patients -neutropenia, peripheral neuropathy on the label market cap: ~$4.5 billion stenoparib, DRP selected (cutoff of 80) from the AACR 2026 poster: -hazard ratio: 0.13 (87% risk reduction) -median OS: not reached, estimated above 25 months(now over 30months in December shareholder latter, now at the end of April) -oral monotherapy, no IV chemo required -zero treatment related deaths -zero thrombocytopenia, zero grade 3-4 neutropenia market cap: ~$19 million

$ALLR when Lilly likes the data nothing stops them

$ALLR and they lit added like $5B mkt cap on this when that announced last yr we r sitting on gold

$ALLR starts around 42:30 for anyone interested. Basically just says volume is really low and needs more demand to move price. Stuff we already know